PDS Biotechnology (NASDAQ:PDSB) Stock Rating Reaffirmed by B. Riley

PDS Biotechnology (NASDAQ:PDSB - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at B. Riley in a research note issued to investors on Thursday, Benzinga reports. They currently have a $11.00 price objective on the stock, down from their previous price objective of $14.00. B. Riley's target price would suggest a potential upside of 177.78% from the company's current price.

A number of other research firms also recently issued reports on PDSB. StockNews.com downgraded shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday, March 16th. HC Wainwright reiterated a "buy" rating and issued a $21.00 price target on shares of PDS Biotechnology in a report on Wednesday. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of PDS Biotechnology in a report on Friday, January 12th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $17.33.

PDS Biotechnology Stock Performance

Shares of PDSB traded up $0.11 during mid-day trading on Thursday, hitting $3.96. 2,283,905 shares of the company's stock were exchanged, compared to its average volume of 883,386. PDS Biotechnology has a fifty-two week low of $3.61 and a fifty-two week high of $10.27. The firm has a market capitalization of $123.20 million, a P/E ratio of -2.32 and a beta of 1.72. The business's 50 day moving average is $5.26 and its two-hundred day moving average is $5.10. The company has a current ratio of 6.21, a quick ratio of 6.21 and a debt-to-equity ratio of 0.96.

Institutional Trading of PDS Biotechnology

Institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in PDS Biotechnology during the fourth quarter worth approximately $124,000. Barclays PLC boosted its stake in PDS Biotechnology by 681.5% in the 4th quarter. Barclays PLC now owns 38,402 shares of the company's stock worth $191,000 after purchasing an additional 33,488 shares during the period. Northern Trust Corp boosted its stake in PDS Biotechnology by 1.3% in the 4th quarter. Northern Trust Corp now owns 249,690 shares of the company's stock worth $1,241,000 after purchasing an additional 3,311 shares during the period. Tower Research Capital LLC TRC lifted its position in PDS Biotechnology by 530.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,046 shares of the company's stock worth $45,000 after buying an additional 7,612 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of PDS Biotechnology during the 4th quarter valued at $52,000. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.